Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1048004-04-1

Post Buying Request

1048004-04-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1048004-04-1 Usage

Chemical structure

A ketone derivative with two pyridine rings attached to a central ethanone group

Field of application

Organic chemistry

Synthesis methods

Various methods available

Potential applications

a. Pharmaceuticals
b. Agrochemicals
c. Materials science

Unique properties

Due to its structure, it has potential for various applications

Biological activities

May have biological activities of interest for further research in medicinal chemistry

Versatility

Has the potential to contribute to various fields of science and industry

Check Digit Verification of cas no

The CAS Registry Mumber 1048004-04-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,8,0,0 and 4 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1048004-04:
(9*1)+(8*0)+(7*4)+(6*8)+(5*0)+(4*0)+(3*4)+(2*0)+(1*4)=101
101 % 10 = 1
So 1048004-04-1 is a valid CAS Registry Number.

1048004-04-1Downstream Products

1048004-04-1Relevant articles and documents

Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect

El-Deeb, Ibrahim Mustafa,Lee, So Ha

experimental part, p. 3860 - 3874 (2010/08/22)

A new series of N-substituted-2-aminopyrimidines based on the '4-(pyridin-3-yl)pyrimidin-2-amine' scaffold of Imatinib has been designed and synthesized. A selected group from the target compounds was tested over a panel of 60 cancer cell lines at a single dose concentration of 10 μM, and the two most active compounds, 25b and 30, were further tested in a five-dose testing mode to determine their IC50 values over the 60 cell lines. Compound 30 has showed good potencies and high efficacies, and was accordingly tested at a single dose concentration of 10 μM over a panel of 54 kinases. At this concentration, the compound has showed multiple inhibitions over a number of oncogenic kinases, including ABL1, AKT1, LCK, C-SRC, PIM1, FLT3, FYN, and KDR. A molecular modeling study was made by docking of the most active compound 30 and its inactive analog 29 into the kinase domain of ABL1 to investigate their possible binding interactions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1048004-04-1